WO2007012976A3 - Airway administration of activated protein c in inflammatory conditions affecting the respiratory tract - Google Patents

Airway administration of activated protein c in inflammatory conditions affecting the respiratory tract Download PDF

Info

Publication number
WO2007012976A3
WO2007012976A3 PCT/IB2006/002773 IB2006002773W WO2007012976A3 WO 2007012976 A3 WO2007012976 A3 WO 2007012976A3 IB 2006002773 W IB2006002773 W IB 2006002773W WO 2007012976 A3 WO2007012976 A3 WO 2007012976A3
Authority
WO
WIPO (PCT)
Prior art keywords
activated protein
respiratory tract
inflammatory conditions
conditions affecting
airway administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/002773
Other languages
French (fr)
Other versions
WO2007012976A2 (en
Inventor
Lars Otto Uttenthal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Drugrecure AS
Original Assignee
Drugrecure AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2006273696A priority Critical patent/AU2006273696B2/en
Priority to RU2008102656/15A priority patent/RU2496515C2/en
Priority to CA2612597A priority patent/CA2612597C/en
Priority to EP06808954.9A priority patent/EP1906994B1/en
Priority to JP2008517630A priority patent/JP2008543926A/en
Priority to CN2006800310622A priority patent/CN101262879B/en
Priority to US11/993,256 priority patent/US20100297099A1/en
Priority to BRPI0613137-9A priority patent/BRPI0613137A2/en
Application filed by Drugrecure AS filed Critical Drugrecure AS
Priority to DK06808954.9T priority patent/DK1906994T3/en
Publication of WO2007012976A2 publication Critical patent/WO2007012976A2/en
Publication of WO2007012976A3 publication Critical patent/WO2007012976A3/en
Priority to IL188221A priority patent/IL188221A0/en
Anticipated expiration legal-status Critical
Priority to NO20080433A priority patent/NO20080433L/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The present invention provides methods for the local treatment of acute and chronic extravascular pulmonary fibrin deposition and/or reducing unwanted effects associated with systemic administration of anticoagulants to a subject via airway administration to the subject by intratracheal, intrabronchial or intraalveolar routes of human activated protein C or biologically active derivatives thereof .
PCT/IB2006/002773 2005-06-24 2006-06-23 Airway administration of activated protein c in inflammatory conditions affecting the respiratory tract Ceased WO2007012976A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US11/993,256 US20100297099A1 (en) 2005-06-24 2006-06-23 Airway Administration of Activated Protein C in Inflammatory Conditions Affecting the Respiratory Tract
CA2612597A CA2612597C (en) 2005-06-24 2006-06-23 Airway administration of activated protein c in inflammatory conditions affecting the respiratory tract
EP06808954.9A EP1906994B1 (en) 2005-06-24 2006-06-23 Airway administration of activated protein c in inflammatory conditions affecting the respiratory tract
JP2008517630A JP2008543926A (en) 2005-06-24 2006-06-23 Respiratory administration of activated protein C in inflammatory conditions affecting the respiratory system
CN2006800310622A CN101262879B (en) 2005-06-24 2006-06-23 Airway administration of activated protein C in inflammatory conditions affecting the respiratory tract
BRPI0613137-9A BRPI0613137A2 (en) 2005-06-24 2006-06-23 airway administration of activated protein c under inflammatory conditions affecting the respiratory tract
DK06808954.9T DK1906994T3 (en) 2005-06-24 2006-06-23 Respiratory tract administration of activated protein C in inflammatory conditions attacking the respiratory organs
AU2006273696A AU2006273696B2 (en) 2005-06-24 2006-06-23 Airway administration of activated protein C in inflammatory conditions affecting the respiratory tract
RU2008102656/15A RU2496515C2 (en) 2005-06-24 2006-06-23 Respiratory introduction of activated protein c in inflammatory conditions involving respiratory tract
IL188221A IL188221A0 (en) 2005-06-24 2007-12-18 Airway administration of activated protein c in inflammatory conditions affecting the respiratory tract
NO20080433A NO20080433L (en) 2005-06-24 2008-01-23 Respiratory tract administration of active protein C in inflammatory conditions affecting the respiratory tract

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69396805P 2005-06-24 2005-06-24
US60/693,968 2005-06-24

Publications (2)

Publication Number Publication Date
WO2007012976A2 WO2007012976A2 (en) 2007-02-01
WO2007012976A3 true WO2007012976A3 (en) 2007-07-12

Family

ID=37570814

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/IB2006/002773 Ceased WO2007012976A2 (en) 2005-06-24 2006-06-23 Airway administration of activated protein c in inflammatory conditions affecting the respiratory tract
PCT/IB2006/002602 Ceased WO2006136962A2 (en) 2005-06-24 2006-06-23 Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract
PCT/IB2006/002631 Ceased WO2006136963A2 (en) 2005-06-24 2006-06-23 Airway administration of site-inactivated fviia in inflammatory conditions affecting the respiratory tract

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/IB2006/002602 Ceased WO2006136962A2 (en) 2005-06-24 2006-06-23 Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract
PCT/IB2006/002631 Ceased WO2006136963A2 (en) 2005-06-24 2006-06-23 Airway administration of site-inactivated fviia in inflammatory conditions affecting the respiratory tract

Country Status (14)

Country Link
US (3) US8088728B2 (en)
EP (3) EP1898945B1 (en)
JP (3) JP2008543926A (en)
KR (2) KR20080071116A (en)
CN (2) CN101262880A (en)
AU (2) AU2006273696B2 (en)
BR (2) BRPI0613137A2 (en)
CA (2) CA2612597C (en)
DK (3) DK1896059T3 (en)
IL (2) IL188221A0 (en)
NO (2) NO20080434L (en)
RU (2) RU2496515C2 (en)
WO (3) WO2007012976A2 (en)
ZA (2) ZA200800251B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010512350A (en) * 2006-12-11 2010-04-22 ダラグレキュル・アンパルトセルスカブ Method for treating cystic fibrosis or pneumonia with bacterial infection by pulmonary administration of fosfomycin
JP6273272B2 (en) 2012-07-04 2018-01-31 ジージー バイオテック エルエルシー Treatment of inflammatory skin disorders
ES2890623T3 (en) 2014-04-16 2022-01-20 Zz Biotech Llc Use of APC analog for wound healing
DK3137102T3 (en) 2014-04-16 2021-10-11 Zz Biotech Llc APC FOR USE FOR THE TREATMENT OF ABNORMAL CUTANE FORMATION
CA3036553A1 (en) * 2016-09-13 2018-03-22 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1273305A1 (en) * 2001-07-06 2003-01-08 Aventis Behring GmbH Medical preparation for inhalation comprising Antithrombin for treating inflammatory lung diseases and ARDS
WO2005042011A1 (en) * 2003-11-04 2005-05-12 Novo Nordisk A/S Pharmaceutical composition comprising a protein c polypeptide and a blood glucose regulator

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5378614A (en) * 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
DK408089D0 (en) * 1989-08-18 1989-08-18 Novo Nordisk As PROTEINS
SE9200541D0 (en) * 1992-02-24 1992-02-24 Kabi Pharmacia Ab NEW USEE OF OMEGA-3-FATTY ACIDS
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
ATE321846T1 (en) * 1996-11-08 2006-04-15 Oklahoma Med Res Found USE OF A MODIFIED PROTEIN-C
US6497877B1 (en) * 1997-01-29 2002-12-24 University Technology Corporation Plasminogen activator as an anti-inflammatory agent
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6049577A (en) * 1998-05-28 2000-04-11 Glenayre Electronics, Inc. Header synchronization detector
AR023819A1 (en) * 1999-05-03 2002-09-04 Astrazeneca Ab PHARMACEUTICAL FORMULATION, KIT OF PARTS AND USE OF THE FORMULATION
JP4848092B2 (en) * 2000-02-01 2011-12-28 石原産業株式会社 Therapeutic or preventive agent for lung failure containing a diaminotrifluoromethylpyridine derivative
AU2001232736A1 (en) * 2000-02-02 2001-08-14 Eli Lilly And Company Protein c derivatives
WO2001058935A2 (en) * 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
US6933367B2 (en) * 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
IL158615A0 (en) * 2001-05-02 2004-05-12 Novo Nordisk As Modified factor vii in treatment of acute lung injury or acute respiratory distress syndrome
BR0213293A (en) * 2001-10-15 2004-12-21 Chiron Corp Use of tfpi or tfpi analog in the treatment of septicemia
KR100674315B1 (en) * 2002-02-08 2007-01-24 에스케이 주식회사 Furnace Tube Cleaners and Cleaning Methods
NZ536796A (en) * 2002-04-25 2007-03-30 Scripps Research Inst Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant
ES2321297T3 (en) * 2003-01-08 2009-06-04 Novartis Vaccines And Diagnostics, Inc. STABILIZED WATER COMPOSITIONS THAT INCLUDE INHIBITOR OF THE TISSULAR FACTOR VIA (IVFT) OR VARIANTE OF THE INHIBITOR OF THE TISSUE FACTOR VIA.
EP1609471A1 (en) * 2003-03-31 2005-12-28 Kyowa Hakko Kogyo Co., Ltd. Remedy and/or preventive for lung diseases
MX2007002903A (en) * 2004-09-10 2007-07-11 Pharmaorigin Aps Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis.
CA2582353A1 (en) 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1273305A1 (en) * 2001-07-06 2003-01-08 Aventis Behring GmbH Medical preparation for inhalation comprising Antithrombin for treating inflammatory lung diseases and ARDS
WO2005042011A1 (en) * 2003-11-04 2005-05-12 Novo Nordisk A/S Pharmaceutical composition comprising a protein c polypeptide and a blood glucose regulator

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
SHIMIZU SHINO ET AL: "Activated protein C inhibits the expression of platelet-derived growth factor in the lung.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 15 MAY 2003, vol. 167, no. 10, 15 May 2003 (2003-05-15), pages 1416 - 1426, XP002426168, ISSN: 1073-449X *
SUZUKI KOJI ET AL: "Protective role of activated protein C in lung and airway remodeling.", CRITICAL CARE MEDICINE MAY 2004, vol. 32, no. 5 Suppl, May 2004 (2004-05-01), pages S262 - S265, XP009081045, ISSN: 0090-3493 *
YASUI H ET AL: "Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE JUN 2001, vol. 163, no. 7, June 2001 (2001-06-01), pages 1660 - 1668, XP002426167, ISSN: 1073-449X *
YUDA HISAMICHI ET AL: "Activated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in mice.", BLOOD 15 MAR 2004, vol. 103, no. 6, 15 March 2004 (2004-03-15), pages 2196 - 2204, XP002426169, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
RU2008102655A (en) 2009-07-27
EP1906994B1 (en) 2014-04-23
EP1896059B1 (en) 2012-12-19
US20100160218A1 (en) 2010-06-24
WO2006136962A2 (en) 2006-12-28
DK1898945T3 (en) 2013-03-25
JP2013151510A (en) 2013-08-08
IL188220A0 (en) 2008-03-20
DK1906994T3 (en) 2014-07-21
NO20080434L (en) 2008-03-17
US8088728B2 (en) 2012-01-03
AU2006273696A1 (en) 2007-02-01
WO2006136962A3 (en) 2007-07-12
CA2612646C (en) 2015-11-24
CA2612597C (en) 2015-03-31
BRPI0613137A2 (en) 2010-12-21
CA2612597A1 (en) 2007-02-01
WO2007012976A2 (en) 2007-02-01
BRPI0611710A2 (en) 2011-12-20
NO20080433L (en) 2008-03-19
ZA200800255B (en) 2009-04-29
CN101262880A (en) 2008-09-10
ZA200800251B (en) 2009-04-29
HK1114567A1 (en) 2008-11-07
DK1896059T3 (en) 2013-04-08
AU2006273696B2 (en) 2012-08-30
EP1898945A2 (en) 2008-03-19
WO2006136963A2 (en) 2006-12-28
IL188221A0 (en) 2008-03-20
EP1906994A2 (en) 2008-04-09
US20100297099A1 (en) 2010-11-25
RU2008102656A (en) 2009-07-27
EP1898945B1 (en) 2012-12-19
AU2006260599A1 (en) 2006-12-28
EP1896059A2 (en) 2008-03-12
RU2496516C2 (en) 2013-10-27
KR20080071116A (en) 2008-08-01
US20100279925A1 (en) 2010-11-04
KR20080074085A (en) 2008-08-12
WO2006136963A3 (en) 2007-07-12
JP2008543925A (en) 2008-12-04
CA2612646A1 (en) 2006-12-28
RU2496515C2 (en) 2013-10-27
CN101262879B (en) 2013-04-10
JP2008543926A (en) 2008-12-04
CN101262879A (en) 2008-09-10

Similar Documents

Publication Publication Date Title
WO2006083989A3 (en) Continuous flow selective delivery of therapeutic gas
WO2006086107A3 (en) Methods and compositions for minimizing accrual of inhalable insulin in the lungs
WO2006105401A3 (en) Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
EP2746290A3 (en) Polypeptides, antibody variable domains and antagonists
WO2007117661A3 (en) Drug microparticles
WO2010094720A3 (en) Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
WO2005117977A3 (en) Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface
WO2007091267A3 (en) Pulmonary delivery of alpha-i proteinase inhibitor
WO2005077103A3 (en) Compositions and methods for modification and prevention of sars coronavirus infectivity
WO2009112274A3 (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
WO2007098106A3 (en) Respiratory tract delivery of interferon-tau
WO2008141786A3 (en) Peptides having the biological activity of vasoactive intestinal peptide (vip) and their use for the treatment of lung diseases
WO2007057714A3 (en) Pharmaceutical compositions comprising methotrexate
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2006136963A3 (en) Airway administration of site-inactivated fviia in inflammatory conditions affecting the respiratory tract
NO20073909L (en) Nebulized formulation
WO2008015695A3 (en) Inclusion complex of olopatadine and cyclodextrin
WO2006100679A3 (en) Recombinant antibodies against human type ii transglutaminase and uses thereof
SE0401631D0 (en) New Composition
WO2006045314A3 (en) Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease
BRPI0515163A (en) methods for treating hemoptysis or local tracheal, bronchial or alveolar bleeding
WO2006017752A3 (en) Sulfated oligosaccharides
EP1843781A4 (en) Composition for prevention, treatment and diagnosis of chronic inflammatory airway diseases
WO2006019894A3 (en) Nebulized pharmaceutical compositions for the treatment of bronchial disorders
JP2008543926A5 (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 188221

Country of ref document: IL

Ref document number: 2612597

Country of ref document: CA

Ref document number: MX/a/2007/016372

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2006273696

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008517630

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 564790

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006808954

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008102656

Country of ref document: RU

Ref document number: 1020087001976

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006273696

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006273696

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200680031062.2

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006808954

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11993256

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0613137

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20071226